Axsome Therapeutics has wrapped its hands around an epilepsy candidate from AstraZeneca through an acquisition of Avenue Therapeutics' subsidiary Baergic Bio, in a deal potentially worth more than $83 million.
<a href="https://www.fiercebiotech.com/biotech/axsome-adds-astrazeneca-epilepsy-candidate-pipeline-through-avenue-subsidiary-acquisition" hreflang="en">Axsome adds AstraZeneca epilepsy candidate to pipeline through Avenue subsidiary acquisition</a>
FierceBiotech | | Darren Incorvaia
Topics: blood-cancer, research